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Abstract: The spread of carbapenem-resistant Enterobacteriaceae (CRE) has been enabled by the lack of
control measures directed at carriers of multidrug-resistant organisms in healthcare settings. Screening
patients for asymptomatic colonization on the one hand, and implementation of contact precautions
on the other hand, reduces patient-to-patient transmission. Screening plates represents a relatively
low-cost method for isolating CRE from rectal swabs; however, molecular assays have become
widely available. This study compared the performance of four commercial molecular platforms in
detecting clinically significant carbapenemase genes versus routine screening for CRE. A total of 1015
non-duplicated rectal swabs were cultured on a chromogenic carbapenem-resistant selective medium.
All growing Enterobacteriaceae strains were tested for carbapenemase-related genes. The same
specimens were processed using the following molecular assays: Allplex™ Entero-DR, Amplidiag®
CarbaR + MCR, AusDiagnostics MT CRE EU, and EasyScreen™ESBL/CPO. The prevalence of Klebsiella
pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae detected by swab culture was 2.2%,
while organisms producing oxacillinase (OXA)-48 and metallo-β-lactamases were infrequent. The cost
of CRE-related infection control precautions, which must be kept in place while waiting for screening
results, are significant, so the molecular tests could become cost-competitive, especially when the
turnaround time is decreased dramatically. Molecular assays represent a powerful diagnostic tool as
they allow the rapid detection of the most clinically relevant carbapenemases.
Keywords: Enterobacteriaceae; multidrug-resistant organisms; asymptomatic colonization; screening
assays
1. Introduction
Antimicrobial resistance is one of the most complex global health challenges [1]. The World
Health Organization puts the development of new antibacterial agents to treat carbapenem-resistant
Enterobacteriaceae (CRE) among the most critical priorities [2]. Because CRE are resistant to the
majority of β-lactams, carbapenem resistance has minimized the usefulness of many commercially
available drugs [3]. In addition to that, CRE frequently carry mechanisms conferring resistance to
other antimicrobial classes, thus further limiting the available therapeutic options [4–6]. Resistance
to carbapenems is typically based on two main mechanisms. The first one is related to structural
mutations combined with the activity of other β-lactamases, such as AmpC cephalosporinase (AmpC)
Microorganisms 2019, 7, 704; doi:10.3390/microorganisms7120704 www.mdpi.com/journal/microorganisms
Microorganisms 2019, 7, 704 2 of 12
and extended spectrum β-lactamases (ESβLs). The second, and likely the most important, mechanism
is carbapenemase enzyme production. These versatile β-lactamases are able to hydrolyze carbapenems
and other β-lactam antibiotics [7–10].
Early reports have described carbapenemases as chromosomally encodedβ-lactamases that hydrolyze
penems and carbapenems. The properties and characteristics of these enzymes are distinctive and
species-specific [11–13].
Plasmid-borne carbapenemases are encoded by genes that are horizontally transferable. This
group includes members of three out of the four β-lactamase classes (A, B, and D), according to the
Ambler classification [14]. Class A and D carbapenemases require serine in the active site. Class
B enzymes require zinc for β-lactam hydrolysis; therefore, they are renamed metallo-β-lactamases
(MBLs). Class A KPC (Klebsiella pneumoniae carbapenemase) enzymes are currently the predominant
carbapenemases reported worldwide among the Enterobacteriaceae [15]. KPC-producing K. pneumoniae
is endemic in several countries, including the United States, Israel, Greece, and Italy [16]. VIM
(Verona integron-encoded metallo-β-lactamase), IMP (active on imipenem), and NDM (New Delhi
metallo-β-lactamase) are the more geographically widespread MBLs [17–19]. Regarding class D
carbapenemases, OXA-48-like-carbapenemases are commonly widespread in enterobacterial species,
especially in Turkey, Middle East, and North Africa. OXA-48-type enzymes show a high level of
hydrolytic activity against penicillins and a low level of hydrolytic activity toward carbapenems [20,21].
The spread of carbapenemase-producing Enterobacteriaceae (CPE) has been sustained and favored
by the combined effects of (i) the widespread use of carbapenems for the management of infections
caused by ESβL-producing Enterobacteriaceae [22,23], (ii) clonal dissemination of particular clinically
relevant strains [24], (iii) interspecies dispersion due to the wide variety of conjugative plasmids, which
are well adapted to different bacteria [25–27], and (iv) co-selection of antibiotic resistance, as the use of
one antibiotic is enough to maintain all drug resistance mechanisms since they are linked together
on the same plasmid [28,29]. CPE are a common cause of healthcare-associated infections as well as
colonization, which is a major source for the transmission of antimicrobial resistance-related genes
inside and outside healthcare institutions [30]. From 2010 onwards, there was an increase in infections
caused by K. pneumoniae resistant to carbapenems in the Emilia-Romagna region in northern Italy.
To control the spread of CPE, a region-wide intervention was carried out based on a regional guideline
issued in July 2011 and subsequently updated in February 2017 [31]. The strategies to reduce CPE
transmission in healthcare settings are focused primarily on the early identification of infected patients
and carriers and on the wide implementation of contact precautions. According to these current
strategies, CPE infections and colonization are diagnosed based on phenotypic methods followed by
phenotypic and/or genotypic confirmation. Additionally, rectal swabs are performed on asymptomatic
carriers as a tool to achieve active surveillance that involves close contact with hospitalized patients
with CPE infection, high-risk patients at hospital admission, and patients admitted to intensive
care units, transplant units, oncology units, and hematology units. All CPE-infected patients and
asymptomatic carriers should be subjected to contact isolation precautions (dedicated nursing staff and
cohorting) during their stay in hospitals [32]. In the context of high CPE prevalence, rapid and accurate
identification of colonized patients is essential for decreasing the diffusion of such microorganisms and
to reduce the costs of all the unnecessary contact precautions [33].
This study evaluated the analytical performance of four commercial molecular technological
platforms for the detection of the most clinically important carbapenemase genes in comparison with
the culture-based routine laboratory method.
2. Materials and Methods
The study was conducted at the Microbiology Unit of the Greater Romagna Area Hub Laboratory,
northeastern Italy, between May and July 2018. The Laboratory serves 1,250,000 inhabitants and
11 hospitals for a total of about 4200 beds.
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A total of 1015 non-duplicated rectal swab specimens were prospectively collected using ESwab™
(COPAN Italia SpA., Brescia, Italy). The samples were transported to the Laboratory upon collection,
processed within 24 h, and reported in 48 h.
2.1. Culture Based and Molecular Routine Methods for the Identification of CRE
Rectal swab specimens were collected as part of the Antimicrobial Resistance Surveillance Program,
in which patients were screened for CRE carriage by rectal swab on admission, according to the hospital
protocols. For the isolation of CRE strains from rectal swab specimens, a 10 µL aliquot from each
specimen was inoculated into a CHROMID® CARBA SMART selective chromogenic media bi-plate
(bioMérieux, Marcy l’Etoile, France).
The plates were incubated at 37 ◦C for 18 h and then examined for growth (Escherichia coli showing
dark pink or red colonies; Klebsiella spp., Enterobacter spp., and Citrobacter spp. showing metallic blue
colonies).
If a swab tested positive, any suspected colony was further identified using the Vitek MS MALDI-ToF
(bioMérieux, Marcy-l’Etoile, France).
Species identification was followed by a molecular test (Xpert® Carba-R test, Cepheid, Sunnyvale,
CA, USA) to detect the gene sequences from pure colonies. The following genes were identified: blaKPC,
blaNDM, blaVIM, blaOXA-48, and blaIMP.
2.2. Molecular Tests
No ethical approval was required because only residual leftover specimens were tested with
the evaluated molecular techniques, and patient data were completely anonymized prior to testing.
All samples underwent an anonymization procedure in order to adhere to the regulations issued by
the local Ethical Board (AVR-PPC P09, rev.2). The following four molecular methods were evaluated:
Allplex™ Entero-DR Assay (Seegene Inc., Seoul, Korea), Amplidiag® CARBAR+MCR (Mobidiag,
Espoo, Finland), AusDiagnostics MT CRE EU Assay (AusDiagnostics, Mascot NSW, Australia), and
EasyScreen™ ESBL/CPO Detection Kit (Genetic Signatures, Newtown NSW, Australia). Almost all
samples were evaluated with the four techniques, with exceptions due to the lack of residual sample
volume or test reagents.
2.2.1. Allplex™ Entero-DR Assay (Seegene Inc., Seoul, Korea)
The rectal eSwabs (number of specimens tested = 1004) were processed using the Allplex™
Entero-DR Assay. Samples were vortexed and loaded in the Microlab STARlet IVD Liquid Handling
Workstation (Hamilton Robotics, Reno, Nevada) with a Universal Extraction Kit (Seegene). DNA
extraction was carried out with 200 µL of primary sample, and DNA was eluted in a volume of 100 µL.
Five microliters of DNA extract was mixed with 20 µL of master mix, and qRT-PCR was performed
using a CFX96 system (Bio-Rad, Hercules, CA, USA). All procedures were performed according to the
manufacturer′s instructions. The test results were interpreted automatically and were presented using
the Seegene Viewer software.
2.2.2. Amplidiag® CARBAR+MCR (Mobidiag, Espoo, Finland)
Automated nucleic acid extraction was performed with 200 µL of primary sample (number of
specimens tested = 1015) using the GENEQUALITY X120 Pathogen kit (Mobidiag). An internal control
was added during this step that served as a process control. Both the extraction and PCR setup were
carried out on the GENEQUALITY X120, based on the STARlet platform (Hamilton Robotics, Cary,
NC, USA). Up to 60 samples can be processed when the two analytical steps are paired. The RT-PCR
amplification reaction was performed on a CFX96 thermal cycler (Bio-Rad). The assay was divided
into three different multiplex reactions, each amplifying a specific group of target genes. The results
were processed and reported by Amplidiag Analyzer software.
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2.2.3. AusDiagnostics MT CRE EU Assay (AusDiagnostics, Mascot NSW, Australia)
A total of 834 rectal eSwab specimens were processed using the AusDiagnostics MT CRE Assay. Since
this platform does not have proprietary extraction technology, DNA was extracted using the same method
as Allplex (5 µL of DNA). The AusDiagnostics MT CRE Assay is based on two different steps. The first
step involves a short 15-cycle pre-amplification reaction using a mixture of primers homologous to each
one of the 14 targets and two internal controls. The amplified product is then diluted into individual
wells for the second step that is dedicated to target specific nested (located inside the sequence used for
step one) amplification. The process is automated using the Easy-Plex liquid handling robotics system
(AusDiagnostics). MT CRE Assay uses two different types of controls: one is a pan-bacterial target
used to validate the sample quality (intrinsic control), and the second is an artificial DNA sequence
used as reference for the semi-quantitation of the different targets (PCR control). The final and overall
evaluation of the results is automatically achieved by MT-PCR Analysis software.
2.2.4. EasyScreen™ ESBL/CPO Detection Kit (Genetic Signatures, Newtown NSW, Australia)
A total of 827 samples were processed using the EasyScreen™ ESBL/CPO Detection Kit. Sample
preparation involved a patented system (3base™) for the conversion of the sample DNA into a synthetic
nucleic acid with a three-base code. A 150 µL liquid specimen was mixed into a lysis buffer containing
a bisulfite reagent, and then it was vortexed and incubated at 95 ◦C for 15 min; this step ensured lysis of
the microorganisms and the universal modification of its nucleic acid into a three-base form, in which
all cytosine bases are converted to thymine through a uracil intermediary. Nucleic acid extraction
and PCR setup were performed on the GS1 Automation System, an instrument based on the Nimbus
platform (Hamilton Robotics). Up to 91 samples can be processed within a single batch. The RT-PCR
amplification reaction was performed on a CFX384 thermal cycler (Bio-Rad). Along with the target
sequences, a universal bacterial sequence was detected as well; this should be endogenously present in
all stool specimens and acts as an extraction control.
3. Results
A total of 1015 rectal surveillance swabs underwent evaluation by culture. The prevalence detected
for KPC-producing Enterobacteriaceae was around 2,2% (22/1015), while the detection of MBLs and
OXA-48 was infrequent (NDM-1 = 2 samples, VIM = 1 sample, OXA-48 = 2 samples).
The number of available tests was different from one molecular assay to another depending on
the reagents made available for this study by the different diagnostic companies (Table 1). However,
the analytical performance of every molecular assay was evaluated, and results were compared with
those found by using the routine culture-based screening technique (Table 2).
Table 1. Detailed results of study specimens.
Assay
Routine Screening Tests
Assay Results Positive Negative Total
Allplex
Entero-DR assay
Positive 25 17 42
Negative 0 940 940
Total 25 957 982
Amplidiag
CarbaR + MCR kit
Positive 20 11 a 31 a
Negative 4 949 953
Total 24 959 983
AusDiagnostics
MT CRE EU assay
Positive 19 5 24
Negative 0 810 810
Total 19 815 834
EasyScreen
ESBL/CPO Detection Kit
Positive 22 5 27
Negative 0 751 751
Total 22 756 778
a A specimen was KPC-positive for routine screening, while with the Amplidiag kit, specimens were positive for
KPC and VIM targets.
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Table 2. Assay performance.
Assay Sensitivity Specificity PPV NPV Overall % Agreement Kappa Statistic
(%[95%CI]) (%[95%CI]) (%[95%CI]) (%[95%CI]) (%[95%CI])
Allplex 100 98.22 59.52
100
98,27
0.74Entero-DR assay (86.28–100) (97.17–98.96) (47.86–70.20) (97.24–98.99)
Amplidiag 83.33 98.85 64.52 99.58 98.48
0.72CARBAR + MCR kit (62.62–95.26) (97.96–99.43) (49.59–77.07) (98.98–99.83) (97.50–99.14)
AusDiagnostics 100 99.39 79.17
100
99.4
0.88MT CRE EU assay (82.35–100) (98.57–99.80) (61.33–90.10) (98.61–99.81)
EasyScreen 100 99.34 81.48
100 99.36 (98.51–99.79) 0.89ESBL/CPO Detection Kit (84.56–100) (98.46–99.78) (64.75–91.33)
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The Allplex™ Entero-DR Assay yielded 982 valid results (42 positives) over 1004 processed swabs.
Data collection was subject to automated analysis by Seegene Viewer software. It is of note that in
22 samples the intrinsic control amplification failed. Subsequently, the PCR control was spiked into the
extracts of the 22 invalidated samples and was amplified to prove the functionality of the reaction mix.
In all 22 samples, the PCR control signal was confirmed, and the presence of inhibitors was excluded.
The Amplidiag® CarbaR+MCR kit yielded 983 valid results (30 positives) over 1015 processed
specimens. The system excluded 32 swabs on the basis of the physical properties of the samples during
the extraction step.
The AusDiagnostics MT CRE EU assay processed 837 DNA samples, which were previously
extracted with the Universal Extraction Kit (Seegene). A total of 834 (24 positives) results were valid;
in 3 cases both the intrinsic and PCR controls were not amplified, likely because of the presence of
inhibitors in these samples.
The EasyScreen™ ESBL/CPO Detection Kit provided 787 valid results over 827 tested specimens
(33 positives). The remaining 40 samples were excluded from analysis for lack of amplification due to
the probable presence of inhibitors.
Every result obtained from each commercial kit was compared with both the routine reference
method and the other three assays. A result was considered discordant if it was not in agreement with
at least one other test taken into account, either culture or molecular methods. Discordant test results
were further analyzed to differentiate them as follows:
blue (Figure 1) results were concordant with the routine screening test but conflicted with at least
one other molecular assay;Microorganisms 2019, 7, x FOR PEER REVIEW  8 of 14 
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red (Figure 1) results were in conflict with routine screening but agreed with at least one other
molecular test; and
green (Figure 1) results were in conflict with both routine screening and all other molecular assays.
Discordant test results are illustrated in Figure 1.
Over 31 total discordant results, the Allplex Entero-DR assay showed 14 tests that were in
agreement with routine screening (7 positive over 14 samples) but conflicted with at least one other
molecular assay (Figure 1. blue). This assay identified 6 samples positive for VIM and, according to
another molecular kit, 2 positive for OXA-48 and 1 positive for KPC. Those 9 samples were not detected
by the routine method (Figure 1. red). Additionally, in 7 specimens, this test only gave a positive
result for single targets including KPC (n=4), VIM (n=1), OXA-48 (n=1), and IMP (n=1). In one rectal
swab, three genes were detected, but not confirmed by any other test, as follows: blaKPC, blaVIM, and
blaIMP (Figure 1. green).
Eighteen Amplidiag® CarbaR+MCR results were in agreement with the cultural screening out
of 33 total discordant results (3 positive over 18 samples) (Figure 1. blue). Nine samples were not
detected by routine screening but were detected according to at least one additional molecular method,
of which 6 were VIMs and 2 were KPCs. In the remaining samples, this method did not show blaKPC,
unlike routine screening, the Allplex Entero-DR assay, and the AusDiagnostics MT CRE EU assay
(Figure 1. red). In 4 cases the detection of VIM was not confirmed by any other technique. In 2 cases
the assay did not detect the KPC target, unlike all other tests (Figure 1. green).
Over 22 total discordant results, the AusDiagnostics MT CRE EU assay showed 17 tests that were
in agreement with routine screening but conflicted with at least one other molecular assay (6 positive
over 17 samples; Figure 1. blue). This assay identified 2 samples positive for VIM, 2 for OXA-48, and 1
for KPC, which were not detected by culture (Figure 1. red). The AusDiagnostics MT CRE EU assay
did not show results in conflict with both routine screening and all other molecular assays.
Eighteen EasyScreen™ ESBL/CPO test results were in agreement with the cultural screening out
of 28 total discordant results (2 positive over 18 samples) (Figure 1. blue). In 2 samples, bla OXA-48
detection was supported by 2 other molecular methods (Allplex Entero-DR and AusDiagnostics MT
CRE EU) but not by culture (Figure 1. red). In 8 specimens the results conflicted with all other tests.
In particular, in 3 cases the KPC target was not detected, and in 5 cases bla OXA-48 was detected only
by this test (Figure 1. green).
4. Discussion
The limited therapeutic options and the high mortality associated with CRE infections impel us to
put in place measures to minimize the chance of transmitting such infective agents from colonized
to non-colonized subjects. Active surveillance to identify asymptomatic carriers is fundamental for
proper care management and for an effective implementation of control measures. On one hand,
screening plates represents a relatively low-cost method for isolating CRE from rectal swabs; on the
other hand, molecular assays for the detection of clinically significant carbapenemase genes have
become widely available in the last years. All patients are clinically evaluated in accordance with a
CPE Control Care Checklist on admission to the healthcare setting. The patients included in one of
the risk categories listed in this checklist are managed for up to 48 h as potential CRE carriers while
waiting for the results of screening cultures to become available.
An internal investigation of the Management of the Greater Romagna Area Health Unit has
estimated the average cost of personal protective equipment at 23 euros/48 h, including all medical
devices required for the contact isolation period. The average cost of CRE screening based on plating
the specimen for growth on selective media, followed by additional testing for isolate confirmation,
is around 2 euros/sample. In comparison, the average cost of CRE screening based on molecular assays
tested in this study was about ten times the price. Taking into account this expense, molecular tests
could become cost-competitive, especially when the turnaround time is decreased dramatically from
48 to about 8 h, and caregivers have the chance to reconsider pre-emptive isolation and to scale back
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contact precautions within the same day of hospital admission. Furthermore, considering laboratory
testing merely in terms of cost does not take into account the added expenses that derive from delayed
results, and the costs of new rapid methods come with an overall reduction in hospital costs and
improvements in patient care.
The four commercial molecular assays evaluated in this study did not require any modifications in the
collection, transport, and storage of rectal swabs routinely processed by culture-based techniques. Loading
collection tubes is convenient, practical, and it reduces errors in the pre-analytical phase (especially
when associated with liquid handling workstations and barcoded materials) such as in the Allplex and
Amplidiag platforms. The AusDiagnostics assay, on the other hand, does not provide a proprietary
extraction system, leaving the choice of the most suitable solution to the laboratory. The sample-to-result
instruments are handy since DNA extraction, amplification, and result interpretation phases are integrated
into a single system; none of the assays evaluated provided this feature. Because of the structures of
these tests, an additional operator intervention is required. Considering the importance of releasing lab
results in the shortest possible time, a suitable assay should be easy for all laboratory personnel to use
and available 24 h/day and 7 days/week. The EasyScreen protocol involves multiple manual steps and
sample transfers, requires considerable attention to avoid sample mix-ups, and has a significantly longer
hands-on time compared to other molecular techniques.
Molecular assays showed results concordant with the reference culture-based method in most
cases. The AusDiagnostics MT CRE EU assay displayed the highest rate of concordance with the
routine cultural screening assay.
Comparisons between results obtained with each commercial platform were only performed for
discordant samples. Concordant test results between two or more molecular techniques, in the case of
a negative reference test, should be considered as likely true positives given the superior sensitivity of
the PCR-based approach [34,35]. The Allplex kit detected the highest number of carbapenemase genes,
according to the other molecular assays, in the absence of growth of carbapenem-resistant colonies.
This improved sensitivity is a key feature in the screening of potential carbapenemase-producing
Enterobacteriaceae carriers; any false negative test result is especially dangerous and undermines the
whole effort of the surveillance program. Amplidiag and EasyScreen were not able to detect resistance
genes in samples that turned out to be positive for CPE in routine testing; this carries the risk of CRE
spreading from colonized subjects to neighboring patients. On the other hand, reliable detection of
CRE carriage is important to optimize public health care resources and to guide hospital infection
control interventions. For this reason, it is recommended to restrict the number of false positives.
Allplex and EasyScreen methods provided the highest number of positive results in conflict with both
routine screening and all other molecular assays.
An additional advantage of molecular methods involves the detection of carbapenemase producers
with low-level resistance, which are difficult to identify with conventional techniques (e.g., OXA-48
producers) [36,37]. Allplex, AusDiagnostics, and EasyScreen assays have shown the presence of the
blaOXA48 gene in some rectal swabs, which were negative for routine methods.
Nucleic acid extraction and purification from fecal specimen suspensions are critical steps when
the molecular approach is selected to diagnose CRE. The extraction control allows the monitoring
of possible problems resulting from poor extraction yield, and the PCR control is designed to detect
inhibition of the polymerase chain reaction. These potential issues could affect the efficiency of PCR
and, consequently, the clinical accuracy of the results provided. The four commercial molecular assays
evaluated in this study were supplied with both extraction and PCR controls. Lower amounts of
amplifiable human DNA make the bacterial 16S rRNA assay a better candidate to control sample
adequacy. A rectal swab quality control check based on visually ensuring the presence of fecal material
does not represent an optimal solution in an automated laboratory workflow; in practice, this is
time-consuming and unreliable. Allplex, AusDiagnostics, and EasyScreen methods provide intrinsic
control in order to ensure sample adequacy.
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Molecular methods have the advantage of directly detecting more than one target in a single test,
thus expanding epidemiological surveillance capabilities. Active surveillance of rectal swabs could
have a positive effect in implementing all evidence-based control measures to protect the health of the
public. The assays evaluated in this study allow the characterization of clinically relevant antibiotic
resistance genes from the most common healthcare-associated MDR bacteria. Genes associated not
only with carbapenem resistance but also with colistin (mcr-1), vancomycin (VanA and VanB), and beta
lactam resistance (e.g., CTX-M) have been detected in different specimens (Table 3).
Table 3. Main characteristics of four commercial molecular kits for detecting carbapenemase genes in
rectal swabs.
Allplex
Entero-DR Assay
Amplidiag CarbaR +
MCR Kit
Ausdiagnostics MT CRE
EU Assay
EasyScreen ESBL/CPO
Detection Kit
Sample throughput up to 94 tests/batch up to 64 tests/batch 24 up to 64 tests/batch up to 80 tests/batch
Hands on time 45 min 1 h 20 min a 3 h
Assay run time 4 h 5 h 2 h a 6 h
Extraction control yes yes yes yes
PCR control yes yes yes yes
intrinsic control yes no yes yes
Other targets vanA; vanB; CTX-M
AcOXA; MCR 1/2;
Guiana
extended-spectrum
(GES)-CPO;
SME; OXA-23,51,58-like;
CTX-M group 1 and
group 9; GES
TEM; DHA; CTX-M;
CMY
SHV; OXA 23; 51-like
Traceability yes yes Depending on DNAextraction system no
a Without extraction step.
The platforms evaluated in this study can perform an array of molecular diagnostic tests in the
area of infectious diseases and also in other areas. Seegene’s platform can perform a wide variety of
tests in infectious diseases (sexually transmitted diseases, respiratory tract and central nervous system
infections, healthcare-associated infections, and surveillance), as a Thrombosis SNPs (single nucleotide
polymorphisms) panel, and in detecting the BRAF mutation (V600E) characteristic of papillary thyroid
carcinoma. Amplidiag® is a family of diagnostic tests for the screening of gastrointestinal pathogens
and antibiotic resistances. Ausdiagnostics has developed a large number of assays in the area of
human infectious diseases (bacterial drug resistance, respiratory tract and central nervous system
infections, enteric pathogens, HPV genotyping), veterinary infectious diseases, and food pathogens.
Genetic Signatures offers a series of assays for the detection of enteric pathogens (bacteria, protozoa,
and viruses).
The spread of CPE in the Emilia-Romagna region, infrequent until 2009, showed a clear increase
in reports of individual cases and hospital epidemics caused by KPC-producing Klebsiella pneumoniae.
Publication of regional guidelines for the control of Carbapenemase-producing Enterobacteriaceae in
July 2011 led to the implementation of an active surveillance program in the Romagna area. In the
following two years a reversal of the trend was observed, which was characterized by a 40% reduction
in CPE carriers among total swabs processed and by a 35% reduction in CPE infections overall among
Enterobacteriaceae isolated from clinical samples. The situation had drastically worsened in 2015
when the number of identified CPE infections more than doubled compared to the previous year. This
change led to expanded screening involving a greater number of patients admitted into different wards.
In 2018 there was a sharp reversal; hospitals experienced a halving of CPE carriers and a 30% decrease
in CPE infections.
Among total isolated CPE, KPC-producing Klebsiella pneumoniae is the germ most frequently found
in rectal swabs and in clinical specimens. Additionally, a sharp increase in the number of carbapenemase-
producing E. coli has been observed. In 2016, the prevalence of carbapenemase-producing E. coli
isolated in the Romagna area was 5,6% over the total 886 CPE strains isolated. This percentage reached
7,8% in 2017 and then increased up to 10,7% in 2018. This tendency confirms the data published by
Del Bianco [38] and poses a serious threat to human health, bearing in mind that E. coli is one of the
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most common members of the intestinal microflora and one of the main pathogens responsible for a
broad spectrum of invasive diseases [39,40]. Carbapenemase-producing E. coli have spread, and the
accumulation of resistance genes has prompted us to undertake upgraded strategies for expediting
the diagnosis of MDR Gram-negative bacteria and for enhancing infection prevention and control in
healthcare settings.
Because of its highest agreement rate, both with routine screening and other molecular methods
evaluated, AusDiagnostics MT CRE EU has proved to be the most reliable assay among the commercial
kits investigated in this study. Additionally, this method provided the lowest number of invalid
samples, and it is supplied with a double internal control system to monitor the influence of possible
inhibitory activities and to ensure sample adequacy. It is noted that this platform does not have
proprietary extraction technology, leaving the choice of extraction method to the laboratory depending
on the existing workflow.
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